MEI Pharma Analyst Ratings
MEI Pharma Analyst Ratings
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a maintained with a price target of $10.00 to $9.00. The current price MEI Pharma (MEIP) is trading at is $7.34, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 22.62% | Stifel | $10 → $9 | Maintains | Hold |
| 05/23/2023 | 989.92% | Brookline Capital | → $80 | Maintains | Buy |
| 05/12/2023 | 36.24% | Stifel | $0.5 → $10 | Maintains | Hold |
| 02/13/2023 | -72.75% | HC Wainwright & Co. | $5 → $2 | Maintains | Buy |
| 02/08/2023 | -98.64% | Jefferies | $0.4 → $0.1 | Downgrades | Hold → Underperform |
| 12/06/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 03/25/2022 | -45.5% | BTIG | $11 → $4 | Maintains | Buy |
| 03/25/2022 | -59.13% | Truist Securities | $8 → $3 | Maintains | Buy |
| 03/25/2022 | -31.88% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/25/2022 | -72.75% | Wells Fargo | $13 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/25/2022 | -72.75% | Stifel | $6 → $2 | Downgrades | Buy → Hold |
| 03/25/2022 | -86.38% | Jefferies | $4 → $1 | Downgrades | Buy → Hold |
| 02/03/2022 | -45.5% | Jefferies | → $4 | Initiates Coverage On | → Buy |
| 05/29/2020 | 117.98% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/13/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/20/2018 | 36.24% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 09/27/2023 | 22.62% | Stifel | 10 美元 → 9 美元 | 维持 | 按住 |
| 05/23/2023 | 989.92% | 布鲁克林资本 | → 80 美元 | 维持 | 购买 |
| 05/12/2023 | 36.24% | Stifel | 0.5 美元 → 10 美元 | 维持 | 按住 |
| 02/13/2023 | -72.75% | HC Wainwright & Co. | 5 美元 → 2 美元 | 维持 | 购买 |
| 02/08/2023 | -98.64% | 杰富瑞集团 | 0.4 美元 → 0.1 美元 | 降级 | 持有 → 表现不佳 |
| 12/06/2022 | — | BTIG | 降级 | 买入 → 中性 | |
| 12/06/2022 | — | Truist 证券 | 降级 | 买入 → 持有 | |
| 03/25/2022 | -45.5% | BTIG | 11 美元 → 4 美元 | 维持 | 购买 |
| 03/25/2022 | -59.13% | Truist 证券 | 8 美元 → 3 美元 | 维持 | 购买 |
| 03/25/2022 | -31.88% | HC Wainwright & Co. | 10 美元 → 5 美元 | 维持 | 购买 |
| 03/25/2022 | -72.75% | 富国银行 | 13 美元 → 2 美元 | 降级 | 超重 → 重量相等 |
| 03/25/2022 | -72.75% | Stifel | 6 美元 → 2 美元 | 降级 | 买入 → 持有 |
| 03/25/2022 | -86.38% | 杰富瑞集团 | 4 美元 → 1 美元 | 降级 | 买入 → 持有 |
| 02/03/2022 | -45.5% | 杰富瑞集团 | → 4 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 5 月 29 日 | 117.98% | SunTrust 罗宾逊·汉弗莱 | → 16 美元 | 启动覆盖范围开启 | → 购买 |
| 02/13/2019 | — | BTIG | 启动覆盖范围开启 | → 购买 | |
| 2018 年 12 月 20 日 | 36.24% | HC Wainwright & Co. | → 10 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的目标价格是多少？
The latest price target for MEI Pharma (NASDAQ: MEIP) was reported by Stifel on September 27, 2023. The analyst firm set a price target for $9.00 expecting MEIP to rise to within 12 months (a possible 22.62% upside). 7 analyst firms have reported ratings in the last year.
Stifel于2023年9月27日公布了MEI Pharma（纳斯达克股票代码：MEIP）的最新目标股价。该分析公司将目标股价定为9.00美元，预计MEIP将在12个月内上涨至9美元（可能上涨22.62％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的最新分析师评级是多少？
The latest analyst rating for MEI Pharma (NASDAQ: MEIP) was provided by Stifel, and MEI Pharma maintained their hold rating.
MEI Pharma（纳斯达克股票代码：MEIP）的最新分析师评级由Stifel提供，MEI Pharma维持其持有评级。
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
MEI Pharma（MEIP）的下一个分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与MEI Pharma的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。MEI Pharma的最后一次评级是在2023年9月27日提交的，因此您应该预计下一个评级将在2024年9月27日左右公布。
Is the Analyst Rating MEI Pharma (MEIP) correct?
分析师对MEI Pharma（MEIP）的评级是否正确？
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a maintained with a price target of $10.00 to $9.00. The current price MEI Pharma (MEIP) is trading at is $7.34, which is out of the analyst's predicted range.
尽管评级是主观的，并将发生变化，但最新的MEI Pharma（MEIP）评级维持不变，目标股价为10.00美元至9.00美元。MEI Pharma（MEIP）目前的交易价格为7.34美元，超出了分析师的预期区间。
译文内容由第三方软件翻译。
